Property:Outcome specification
This is a property of type Text.
M
Mantovani et al. (2010): Randomized Phase III Clinical Trial of Five Different Arms of Treatment in 332 Patients with Cancer Cachexia +
NA +
Margalit et al. (2012): Beta-carotene Antioxidant Use During Radiation Therapy and Prostate Cancer Outcome in the Physicians’ Health Study +
Time from radiation therapy initiation to lethal prostate cancer (death from prostate cancer or participant-reported bone metastases among living participants) +
Martin et al. (2002): Does prophylactic treatment with proteolytic enzymes reduce acute toxicity of adjuvant pelvic irradiation? Results of a double-blind randomized trial +
Requirements for supportive medication due to acute toxicities evaluated on T1 = day 3 of radiation to T6 = day 35 of radiation +
Martin et al. (2002): Does prophylactic treatment with proteolytic enzymes reduce acute toxicity of adjuvant pelvic irradiation? Results of a double-blind randomized trial +
Evaluation of acute toxicity was done by the radiation oncologist together with the patient in an interview. Diarrhea was assessed by increase of stools per day. Vomiting was assessed by frequency per day. Nausea was assessed by decrease of food intake.The fatigue syndrome was assessed by loss of activity. +
Martin et al. (2002): Does prophylactic treatment with proteolytic enzymes reduce acute toxicity of adjuvant pelvic irradiation? Results of a double-blind randomized trial +
Treatment interruption (in days) or premature end of radiation therapy due to radiation-induced side effects +
Marucci et al. (2017): Double-blind randomized phase III study comparing a mixture of natural agents versus placebo in the prevention of acute mucositis during chemoradiotherapy for head and neck cancer +
During weekly visits patients underwent a structured interview and physical examination by both a nurse and a radiation oncologist. At each visit, the following items were scored: objective mucositis (CTCAE), functional mucositis (CTCAE) and dysphagia (CTCAE). +
Marucci et al. (2017): Double-blind randomized phase III study comparing a mixture of natural agents versus placebo in the prevention of acute mucositis during chemoradiotherapy for head and neck cancer +
During weekly visits patients underwent a structured interview and physical examination by both a nurse and a radiation oncologist. At each visit, the following items were scored: pain control (Verbal descriptor scale).
Peak pain:
(0) None
(1) Slight
(2) Moderate
(3) Severe
(4) Extreme
(5) As bad as it can be +
Marx et al. (2017): The Effect of a Standardized Ginger Extract on Chemotherapy-Induced Nausea-Related Quality of Life in Patients Undergoing Moderately or Highly Emetogenic Chemotherapy: A Double Blind, Randomized, Placebo Controlled Trial +
Prognostic factors (age, gender, anticipated CINV, chemotherapy emetogenicity) +
Marx et al. (2017): The Effect of a Standardized Ginger Extract on Chemotherapy-Induced Nausea-Related Quality of Life in Patients Undergoing Moderately or Highly Emetogenic Chemotherapy: A Double Blind, Randomized, Placebo Controlled Trial +
Nutrition status at T2 (at the day of chemotherapy) +
Marx et al. (2017): The Effect of a Standardized Ginger Extract on Chemotherapy-Induced Nausea-Related Quality of Life in Patients Undergoing Moderately or Highly Emetogenic Chemotherapy: A Double Blind, Randomized, Placebo Controlled Trial +
Adverse events +
Marx et al. (2017): The Effect of a Standardized Ginger Extract on Chemotherapy-Induced Nausea-Related Quality of Life in Patients Undergoing Moderately or Highly Emetogenic Chemotherapy: A Double Blind, Randomized, Placebo Controlled Trial +
Global cancer-associated quality of life (FACT-G). For T0 (Baseline) and T6 (4th day after chemotherapy) +
Marx et al. (2017): The Effect of a Standardized Ginger Extract on Chemotherapy-Induced Nausea-Related Quality of Life in Patients Undergoing Moderately or Highly Emetogenic Chemotherapy: A Double Blind, Randomized, Placebo Controlled Trial +
CINV-dependent quality of life (QoL) at T0 (baseline), T6 (4th day after chemotherapy) +
Marx et al. (2017): The Effect of a Standardized Ginger Extract on Chemotherapy-Induced Nausea-Related Quality of Life in Patients Undergoing Moderately or Highly Emetogenic Chemotherapy: A Double Blind, Randomized, Placebo Controlled Trial +
At baseline and T6 (Day 4 after chemotherapy) +
Marx et al. (2017): The Effect of a Standardized Ginger Extract on Chemotherapy-Induced Nausea-Related Quality of Life in Patients Undergoing Moderately or Highly Emetogenic Chemotherapy: A Double Blind, Randomized, Placebo Controlled Trial +
CINV symptoms: Nausea, retching, vomiting. To T1-T6 (1 day before chemotherapy - 4th day after chemotherapy) +
Mayne et al. (2001): Randomized Trial of Supplemental beta-Carotene to Prevent Second Head and Neck Cancer +
a) Incidence of local recurrence alone
b) Incidence of second primary tumor alone +
Mayne et al. (2001): Randomized Trial of Supplemental beta-Carotene to Prevent Second Head and Neck Cancer +
Local recurrence AND second primary tumor in one person at the same time +
Mayne et al. (2001): Randomized Trial of Supplemental beta-Carotene to Prevent Second Head and Neck Cancer +
Specific results for:
a) age of death
b) stratification with regard to smoking history (less than 25 pack/year vs. more than 25 pack/year
c) stratification with regard to plasma beta-carotene +
Mayne et al. (2001): Randomized Trial of Supplemental beta-Carotene to Prevent Second Head and Neck Cancer +
Combined incidence of local recurrence or second primary tumor (head and neck, esophagus or lung) +
Mazdak et al. (2012): Vitamin E reduces superficial bladder cancer recurrence: A randomized controlled Trial +
Occurrence of recurrences +
Meyskens et al. (1995): Effects of vitamin A on survival in patients with chronic myelogenous leukemia: a SWOG randomized trial +
Measured from randomization until death from any cause +